About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET.
The company, which specializes in artificial intelligence (AI) functionalities to aid drug discovery, could be a powerhouse, according to one market professional.
Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a peer reviewed study in Genetics in Medicine.
October 20, 2025 - The artificial intelligence (AI) sector continues to be a dominant force in the financial markets, driving significant gains and pushing major indices to new highs. Despite a backdrop of global economic uncertainty and geopolitical tensions, AI-related stocks have demonstrated exceptional performance throughout 2025, with some companies
Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical genetics to improve patient care and to support fair access to genetic services. The study presents a comprehensive analysis of 10 years of exome reanalysis data across diverse racial, ethnic, and ancestral (REA) groups.
Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos, F5, Klarna, Leonardo DRS, and First Horizon, driven by sector pullbacks, policy concerns on defense buybacks, a high-profile cyber breach, and weak earnings.
Whitehawk Therapeutics shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI to support the development of its oncology pipeline.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus’ proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics’ oncology pipeline.
After hitting $100, Tempus AI has retreated, but shares have still provided huge returns. Multiple factors suggest that the stock could see a larger correction.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.
Shared stocks between Nancy Pelosi and Cathie Wood include Alphabet, Amazon, NVIDIA, and Tempus AI. They also both own stakes in private company Databricks.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers to target metastatic disease, initially focusing on non-small cell lung, breast, and colorectal cancers, with the ultimate goal of improving patient survival.
